Evaluation of her2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

HIGHLIGHTS

• who: Camerini et_al et al. from the (UNIVERSITY) have published the paper: Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer, in the Journal: (JOURNAL) of 11/04/2011
• what: The authors explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer.
• how: Using this mean value as cut-off to distinguish high and low expressing tumors staining was considered high in 11 (30.5%) out of 36 tumors in the series (similar results were obtained using . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.